Ginkgo Bioworks Holdings (DNA) Income from Non-Controlling Interests (2020 - 2022)
Ginkgo Bioworks Holdings' (DNA) quarterly Income from Non-Controlling Interests came in at $2.4 million in Q4 2022, up 155.08% YoY from $936954.3 in Q4 2021, and up 236.96% on a QoQ basis from -$1.7 million in Q2 2022.
Ginkgo Bioworks Holdings (DNA) Income from Non-Controlling Interests (2020 - 2022) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 3 years of Income from Non-Controlling Interests data on file, last reported at $2.4 million in Q4 2022.
- Quarterly Income from Non-Controlling Interests rose 155.08% year-over-year to $2.4 million in Q4 2022, while the trailing twelve-month figure through Sep 2023 was $2.4 million (up 129.25% YoY) and the FY2022 annual result came in at -$1.4 million, up 78.12% from the prior year.
- Income from Non-Controlling Interests improved to $2.4 million in Q4 2022, from -$1.7 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $2.4 million in Q4 2022 to a low of -$4.3 million in Q4 2021.
- A 3-year average of -$968888.9 and a median of -$753000.0 in 2020 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2021 — Income from Non-Controlling Interests tumbled 838.03% — and 2022, when it surged 155.08%.
- Tracing DNA's Income from Non-Controlling Interests over 3 years: stood at -$753000.0 in 2020, then tumbled by 476.23% to -$4.3 million in 2021, then surged by 155.08% to $2.4 million in 2022.
- The last three Income from Non-Controlling Interests figures came in at $2.4 million (Q4 2022), -$1.7 million (Q2 2022), and -$2.1 million (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 2.39 Mn |
| Jun 30, 2022 | -1.75 Mn |
| Mar 31, 2022 | -2.09 Mn |
| Dec 31, 2021 | -4.34 Mn |
| Sep 30, 2021 | -524,000.00 |
| Jun 30, 2021 | -523,000.00 |
| Mar 31, 2021 | -1.21 Mn |
| Dec 31, 2020 | -753,000.00 |
| Sep 30, 2020 | 71,000.00 |